An interventional study of AI software in Multiple Sclerosis, sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Queen Mary University of London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Multiple Sclerosis with a site in United Kingdom — 28 open to participants now, 46 under way, 11 of them phase 3. Multiple Sclerosis · United Kingdom.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, this one is the 11th largest by planned enrollment of the 195 interventional ones that give a count, is one of 9 that started in 2025, is one of 43 with no phase, reaches primary completion later than 20 of the 45 other live ones, and was the 240th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →28 of the 252 studies in Multiple Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Aston University · Sites in United Kingdom
Ages 2–16 · Healthy volunteers
Swansea University · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–60
Oxford University Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 47 · Phase 3 72 · Phase 4 15
First in 1999; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,336 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 136 across the 195 interventional studies, 200 across the 57 observational. Of the 187 that completed or were terminated, 95 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 252 have an industry lead sponsor. The 10 most frequent:
Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Queen Mary University of London has 9 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Multiple Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT06274671University of ExeterGlymphatic MRI in Clinically Isolated Syndrome | 2026-12-31 |
| NCT07452562Swansea UniversityHesperidin RCT in MS | 2027-01-18 |
| NCT07111637Queen Mary University of LondonArtificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis | 2027-04-14 |
| NCT06900244University of OxfordMetabolic Imaging of Neurological Disease | 2027-06 |
Add all 11 to your calendar (.ics) → With an account.
Among the 252 studies in Multiple Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing Multiple Sclerosis (MS). It is also essential to monitor the treatment to see if it is working and to switch treatments if needed.
Magnetic resonance imaging (MRI) is the only accepted tool to monitor how well the treatment is working. Current evaluation of brain Magnetic resonance imaging (MRI) scans requires visual inspection, of which sensitivity is degraded by human, and technical factors, such as lack of time, fatigue of radiologists, and lack of standardization of image acquisition protocols across the National Health Service (NHS). MRI-readings can be significantly enhanced by artificial intelligence (AI)-assistive software. Evidence suggests the rate of new lesion detection to be 3 - 4 times higher when using assistive software compared to visual inspection of MRI scans.
In this study, an Artificial Intelligence (AI) software called "icobrain ms." developed by the company "icometrix" (Leuven, Belgium) is tested. This tool helps track MS by measuring changes in the brain using MRI scans. The AI can highlight problem areas and create reports that doctors can use to make better decisions about participants' treatment. The aim of the study is to prove that icobrain ms can be used to assist the neuro-radiologist with their visual assessment of MRI scans by a radiologist, and that it will help clinicians make more informed decisions about participants' current MS treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
icobrain ms Artificial Intelligence (AI) assistive software
Device: AI software
Standard of Care
icobrain ms is an Artificial Intelligence (AI)-assistive software which quantifies brain Magnetic Resonance Imaging (MRIs) and summarises clinically relevant findings for patients with Multiple Sclerosis in structured electronic radiological reports and annotated images.
To assess the clinical usefulness of icobrain ms by evaluating the detection of disease activity (as defined by new/expanding lesions).
Time frame: From enrollment to the end of treatment at 12 months
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 22 months is close to that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →